2015
DOI: 10.5935/0101-2800.20150071
|View full text |Cite
|
Sign up to set email alerts
|

Risk factors for acute kidney injury in patients treated with polymyxin B at a Tertiary Care Medical Center

Abstract: In this retrospective cohort, nephrotoxicity (as defined by RIFLE criteria) occurred among 43% of treated patients. The concomitant use of vancomycin and hypotension were independent risk factors of nephropathy. Further studies are needed, particularly with polymyxin B, to clarify if the characteristics of this drug and colistin are overlapping.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0
7

Year Published

2017
2017
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(14 citation statements)
references
References 16 publications
0
7
0
7
Order By: Relevance
“…La frecuencia de nefrotoxicidad observada se encuentra dentro de los rangos ampliamente reportados en la literatura médica (14-60%) 9,10,12,[14][15][16] . Confirmando los hallazgos previamente descritos por Oliveira, y cols.…”
Section: Discussionunclassified
See 2 more Smart Citations
“…La frecuencia de nefrotoxicidad observada se encuentra dentro de los rangos ampliamente reportados en la literatura médica (14-60%) 9,10,12,[14][15][16] . Confirmando los hallazgos previamente descritos por Oliveira, y cols.…”
Section: Discussionunclassified
“…y Akajagbor y cols. 15,18 , quienes documentaron en sus estudios mayor nefrotoxicidad en pacientes con creatininemia anormal al inicio del tratamiento.…”
Section: Discussionunclassified
See 1 more Smart Citation
“…Few studies tried to identify the factors associated with renal injury with polymyxin B. Bahlis et al [52] in a retrospective cohort study identified 43% patients of renal injury by RIFLE (Risk, Injury, and Failure; Loss; and End-stage kidney disease) criteria. They observed hypotension (OR 2.79; p = 0.006) and concomitant vancomycin use (OR 2.79; p = 00.011) as independent predictors of renal injury.…”
Section: Efficacy Of Polymyxin B: Combination Therapymentioning
confidence: 99%
“…La colistina es un bactericida tipo polimixina (polimixina E), eficaz contra bacilos gramnegativos, (7) principalmente útil contra gérmenes multirresistentes . Existen pocas referencias sobre los efectos adversos medicamentosos asociados, pero los estudios más recientes destacan dos sistemas (8,9) afectados más frecuentes: la neuro y la nefrotoxicidad . La nefrotoxicidad inducida por colistina, aunque no muy bien definida, parece ser influenciada por el perfil renal alterado previo, patologías subyacentes e hipoflujo renal.…”
unclassified